1. BCR-ABL as a molecular target / Michael Deininger -- 2. Allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia / Mukta Arora and Mary M. Horowitz --3. Where Are We Today with Imatinib Therapy? / John M. Goldman -- 4. Monitoring chronic myeloid leukemia in 2006 / Nicola Hurst, Timothy P. Hughes, and Susan Branford -- 5. Dasatinib : a dual ABL and SRC inhibitor / Alfonso Quintas-Cardama, Hagop Kantarjian, and Jorge Cortes -- 6. Nilotinib (AMN107) for the treatment of chronic myelogenous leukemia / Elias Jabbour. [et al.] -- 7. Resistance to imatinib / Justus Duyster and Nikolas von Bubnoff -- 8. Immunotherapy of chronic myeloid leukemia / Monica Bocchia and Francesco Lauria -- 9. Molecular targets other than Bcr-Abl : how to incorporate them into the CML therapy? / Junia V. Melo and David J. Barnes -- 10. Blastic transformation of chronic myelogenous leukemia : does BCR-ABL orchestrate disease progression? / Bruno Calabretta and Danilo Perrotti -- 11. Early intensification of therapy : the role of high-dose imatinib and imatinib-based combinations / Francois Guilhot. [et al.].